V. Pokrovskiy

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.

M. Noor, N. Sosa, E. Arathoon, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Serological diagnosis and prevalence of HIV-1 infection in Russian metropolitan areas

C. Galli, E. B. Zueva, A. Semenov, 2021, BMC Infectious Diseases.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

B. Clotet, M. Saag, A. Antinori, 2014, The Lancet.

Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir

G. Pantaleo, P. Cahn, P. Phanuphak, 2004, Journal of acquired immune deficiency syndromes.

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

J. Gatell, A. Vibhagool, A. Lazzarin, 2004, Journal of acquired immune deficiency syndromes.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

[Opportunities for use the cascade model of medical care for people living with HIV].

V. Akimkin, A. Pokrovskaya, V. Pokrovskiy, 2020, Terapevticheskii arkhiv.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

The HIV integrase inhibitor raltegravir as part of antiretroviral therapy schemes in patients with HIV infection and hepatitis C

L. A. Gurkina, O. Kozyrev, E. Ivanova, 2015 .